AMGEN USA INC - NEW AWARD FOR TRASTUZUMAB WITH AMGEN. ORDERING PERIOD IS NOV 15, 2025 THROUGH NOV 14, 2026 WITH FOUR ONE-YEAR OPTIONS.
Key Details
Description
NEW AWARD FOR TRASTUZUMAB WITH AMGEN. ORDERING PERIOD IS NOV 15, 2025 THROUGH NOV 14, 2026 WITH FOUR ONE-YEAR OPTIONS.
Context & Analysis
On Jan 20, 2026, Department of Veterans Affairs to AMGEN USA INC for new award for trastuzumab with amgen. ordering period is nov 15, 2025 through nov 14, 2026 with four one-year options.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 3 offers received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.